Cairo Pharmaceuticals results, Fiscal year 2021
Net profit, assets, equity and cash flow for Fiscal year 2021, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit124 millionEGP
Total assets1.07 billionEGP
Shareholders' equity704 millionEGP
Operating cash flow162 millionEGP
In short
- Cairo Pharmaceuticals's net profit for Fiscal year 2021 was about 124 million EGP.
- Total assets at the end of Fiscal year 2021 were about 1.07 billion EGP, and shareholders' equity about 704 million EGP.
- Operating cash flow for Fiscal year 2021 was positive at 162 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit124 million——
Gross profit268 million——
Total assets1.07 billion——
Total liabilities365 million——
Shareholders' equity704 million——
Total liabilities and equity1.07 billion——
Operating cash flow162 million——
Investing cash flow-35.13 million——
Financing cash flow-77.73 million——
Net change in cash49.39 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy